Merck & Co., Inc. (MRK), Tuesday announced positive topline results from the Phase 2 CADENCE study of WINREVAIR, a brand name for sotatercept-csrk, in adults with combined post- and pre-capillary pulmonary hypertension due to heart failure with preserved ejection fraction.
The randomized, double-blind randomized, placebo-controlled Phase 2 proof-of-concept study evaluated the efficacy and safety of WINREVAIR versus placebo in the participants.
At the end of 24 weeks, the study met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in pulmonary vascular resistance, an important hemodynamic measurement related to cardiac and pulmonary blood vessel function, from baseline compared to placebo.
Also, based on a preliminary assessment, the safety profile observed in the study was generally consistent with the known safety profile for WINREVAIR. The company plans to present these results at a future scientific congress and intends to proceed with Phase 3 development.
In the pre-market hours, MRK is trading at $96, up 3.36 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.